Page 67 - Read Online

Farkas et al. J Cancer Metastasis Treat 2022;8:37 https://dx.doi.org/10.20517/2394-4722.2022.89 Page 13 of 13

pleural and peritoneal mesothelioma, New South Wales, 1972-2009. Aust N Z J Public Health 2016;40:255-62. DOI PubMed
53. Pavlisko EN, Liu B, Green C, Sporn TA, Roggli VL. Malignant diffuse mesothelioma in women: a study of 354 cases. Am J Surg
Pathol 2020;44:293-304. DOI PubMed
54. Thomas A, Chen Y, Yu T, Gill A, Prasad V. Distinctive clinical characteristics of malignant mesothelioma in young patients.
Oncotarget 2015;6:16766-73. DOI PubMed PMC
55. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the dana-farber cancer
institute and brigham and women’s hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53. DOI PubMed
56. Le Stang N, Bouvier V, Glehen O, et al. Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A
population-based study. Cancer Epidemiol 2019;60:106-11. DOI PubMed
57. Chapel DB, Schulte JJ, Absenger G, et al. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic
parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol 2021;34:380-95. DOI
PubMed
58. Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal
mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686-93. DOI PubMed
59. Pavlisko EN, Roggli VL. Sarcomatoid peritoneal mesothelioma: clinicopathologic correlation of 13 cases. Am J Surg Pathol
2015;39:1568-75. DOI PubMed
60. Malpica A, Euscher ED, Marques-Piubelli ML, et al. Malignant mesothelioma of the peritoneum in women: a clinicopathologic study
of 164 cases. Am J Surg Pathol 2021;45:45-58. DOI PubMed
61. Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: Implications for diagnosis and histogenesis. Semin
Diagn Pathol 1992;9:151-61. PubMed
62. Dacic S, Roy S, Lyons MA, von der Thusen JH, Galateau-Salle F, Churg A. Whole exome sequencing reveals BAP1 somatic
abnormalities in mesothelioma in situ. Lung Cancer 2020;149:1-4. DOI PubMed
63. Churg A, Hwang H, Tan L, et al. Malignant mesothelioma in situ. Histopathology 2018;72:1033-8. DOI PubMed
64. Fels Elliott DR, Travieso JL, As-Sanie S, et al. Progression of peritoneal mesothelioma in situ to invasive mesothelioma arising in the
setting of endometriosis with germline BAP1 mutation: a case report. Int J Gynecol Pathol 2022;41:535-40. DOI PubMed
65. Churg A, Dacic S, Galateau-Salle F, Attanoos R, de Perrot M. Malignant mesothelioma in situ: clinical and pathologic implications. J
Thorac Oncol 2020;15:899-901. DOI PubMed
66. Churg A, Galateau-Salle F, Roden AC, et al. Malignant mesothelioma in situ: morphologic features and clinical outcome. Mod Pathol
2020;33:297-302. DOI PubMed
67. Klebe S, Nakatani Y, Dobra K, et al. The concept of mesothelioma in situ, with consideration of its potential impact on cytology
diagnosis. Pathology 2021;53:446-53. DOI PubMed
68. Pulford E, Henderson DW, Klebe S. Malignant mesothelioma in situ: diagnostic and clinical considerations. Pathology 2020;52:635-
42. DOI PubMed